Related Experiment Videos

Thiazolidinediones-improving endothelial function and potential long-term benefits on cardiovascular disease in

Paresh Dandona1, Husam Ghanim, Ajay Chaudhuri

  • 1Division of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo and Kaleida Health, 3 Gates Circle, Buffalo, NY 14209, USA. pdandona@kaleidahealth.org

Journal of Diabetes and Its Complications
|January 15, 2008
PubMed

Insights

Thiazolidinediones improve endothelial function, crucial for preventing atherosclerosis and cardiovascular disease. These agents combat inflammation and thrombosis, benefiting patients with and without type 2 diabetes.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Endothelial dysfunction, characterized by impaired vasodilation, is an early indicator of atherosclerosis.
  • Insulin resistance, hyperglycemia, and metabolic abnormalities accelerate endothelial dysfunction and cardiovascular disease risk.
  • The endothelium plays a vital role in repairing damage after cardiovascular events.

Purpose of the Study:

  • To investigate the impact of thiazolidinediones on endothelial function.
  • To evaluate the anti-inflammatory and antithrombotic properties of thiazolidinediones.
  • To assess the clinical benefits of thiazolidinediones in atherosclerosis and type 2 diabetes.

Main Methods:

  • Review of recent studies on thiazolidinediones and endothelial function.
  • Analysis of clinical trials examining thiazolidinediones' effects on cardiovascular risk factors.
  • Evaluation of mechanisms underlying thiazolidinediones' impact on endothelial health.

Main Results:

  • Thiazolidinediones demonstrate significant improvements in endothelial function.
  • These agents possess anti-inflammatory and antithrombotic properties.
  • Clinical benefits extend to subjects with and without type 2 diabetes.

Conclusions:

  • Thiazolidinediones represent a promising therapeutic strategy for improving endothelial function.
  • Their multifaceted actions may positively influence the progression of atherosclerosis.
  • Further research is warranted to fully elucidate their role in cardiovascular disease prevention.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...